Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE Trial: Immunotherapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
NCT04510597Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2021
- Primary completion
- Jul 2033
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 7 years. Started Mar 2021; status: recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04510597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510597.